This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.theguardian.com/world/2014/nov/26/ebola-vaccine-trial-results-promising-glaxosmithkline

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Ebola vaccine trial results promising, says manufacturer Ebola vaccine trial results promising, says manufacturer
(about 1 hour later)
Preliminary results from trials in human volunteers of one of the leading Ebola vaccine candidates are promising, according to the British drug company manufacturing it. Preliminary results from trials in human volunteers of one of the leading Ebola vaccine candidates are promising, according to its British manufacturers.
GlaxoSmithKline’s vaccine, developed with the National Institutes of Health in the US, is one of three that are being speeded into trials in the Ebola-hit countries of west Africa. It is hoped that they can be tested in healthcare workers, burial teams and others at high risk of infection in January. GlaxoSmithKline’s vaccine, developed with the National Institutes of Health in the US, is one of three being speeded into trials in the Ebola-hit countries of west Africa. It is hoped that they can be tested on healthcare workers, burial teams and others at high risk of infection in January.
The results were published in the New England Journal of Medicine as the World Health Organisation updated the numbers of people affected by the Ebola epidemic. By the end of November 23, it said, there had been 15,935 reported cases and 5,689 deaths. The true figures are thought to be much higher. The results were published in the New England Journal of Medicine as the World Health Organisation updated the numbers of people affected by the Ebola epidemic. By the end of November 23, it said, there had been 15,935 reported cases and 5,689 deaths. The actual figures are thought to be much higher.
Before any of the vaccines can be trialled in the region, they must go through safety testing. Results from the vaccination of the first healthy volunteers in the United States show no ill-effects and all 20 developed antibodies to the virus, said the paper. All vaccines must go through safety testing. Results from the vaccination of the first healthy volunteers in the United States show no ill-effects. All 20 developed antibodies to the virus, according to the paper.
“We are very encouraged by these positive first trial results showing this type of vaccine has an acceptable safety profile and can produce an immune response against Ebola in humans,” said Dr Moncef Slaoui, chairman of Global Vaccines at GSK. “We are very encouraged by these positive first trial results showing this type of vaccine has an acceptable safety profile and can produce an immune response against Ebola in humans,” said Dr Moncef Slaoui, chairman of global vaccines at GSK.
“It’s important to remember that these data are the first piece in the jigsaw and we’re continuing to gather other important information. Over the coming weeks, we will see results from further phase 1 trials which will tell us more about the profile of the monovalent vaccine; most significantly results from a trial in Mali which is assessing its safety and immune response in West African populations.”“It’s important to remember that these data are the first piece in the jigsaw and we’re continuing to gather other important information. Over the coming weeks, we will see results from further phase 1 trials which will tell us more about the profile of the monovalent vaccine; most significantly results from a trial in Mali which is assessing its safety and immune response in West African populations.”
If the results are all positive, thousands of volunteers including healthcare workers will be vaccinated in early 2015 in Liberia and Sierra Leone and possibly also Guinea, he said. “If the candidate vaccine is able to protect these healthcare workers as we hope it will, it could significantly contribute to efforts to bring this epidemic under control,” he said.If the results are all positive, thousands of volunteers including healthcare workers will be vaccinated in early 2015 in Liberia and Sierra Leone and possibly also Guinea, he said. “If the candidate vaccine is able to protect these healthcare workers as we hope it will, it could significantly contribute to efforts to bring this epidemic under control,” he said.